Single-cell DNA sequencing uncovers clonal evolution and therapeutic resistance in monoclonal gammopathies, indicating new biomarker screening may enhance clinical outcomes.
Key Points
Therapeutic resistance mechanisms were identified through genomic data linked to treatment responses.
In patients with monoclonal gammopathies, clonal evolution showed unique patterns of genomic alterations.
Single-cell DNA sequencing combined with surface protein profiling revealed significant therapeutic targets.
These findings emphasize the importance of biomarker screening to predict treatment response in plasma cell disorders.